Song Joo Y, Pittaluga Stefania, Dunleavy Kieron, Grant Nicole, White Therese, Jiang Liuyan, Davies-Hill Theresa, Raffeld Mark, Wilson Wyndham H, Jaffe Elaine S
*Laboratory of Pathology ‡Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD †Department of Pathology and Laboratory Medicine, City of Hope Medical Center, Duarte, CA §Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL.
Am J Surg Pathol. 2015 Feb;39(2):141-56. doi: 10.1097/PAS.0000000000000328.
Lymphomatoid granulomatosis (LYG) is a rare angiocentric and angiodestructive Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorder. It is hypothesized that these patients have dysregulated immune surveillance of EBV. We reviewed the biopsies of 55 patients with LYG who were referred for a prospective trial at the National Cancer Institute (1995 to 2010) and evaluated the histologic, immunohistochemical, in situ hybridization, and molecular findings of these biopsies in conjunction with clinical information. Grading of the lesions was based on morphologic features and the number of EBV-positive B cells. The median age was 46 years (M:F 2.2:1). Clinically, all patients had lung involvement (100%), with the next most common site being the central nervous system (38%). No patient had nodal or bone marrow disease. All patients had past EBV exposure by serology but with a low median EBV viral load. We reviewed 122 biopsies; the most common site was lung (73%), followed by skin/subcutaneous tissue (17%); other sites included kidney, nasal cavity, gastrointestinal tract, conjunctiva, liver, and adrenal gland. Histologically, the lesions showed angiocentricity, were rich in T cells, had large atypical B cells, and were positive for EBV. Grading was performed predominantly on the lung biopsy at diagnosis; they were distributed as follows: LYG grade 1 (30%), grade 2 (22%), and grade 3 (48%). Necrosis was seen in all grades, with a greater degree in high-grade lesions. Immunoglobulin gene rearrangement studies were performed, and a higher percentage of clonal rearrangements were seen in LYG grade 2 (50%) and grade 3 (69%) as compared with grade 1 (8%). LYG is a distinct entity that can usually be differentiated from other EBV-associated B-cell lymphoproliferative disorders on the basis of the combination of clinical presentation, histology, and EBV studies. Grading of these lesions is important because it dictates the treatment choice.
淋巴瘤样肉芽肿病(LYG)是一种罕见的、以血管为中心且具有血管破坏性的、与爱泼斯坦-巴尔病毒(EBV)相关的B细胞淋巴增殖性疾病。据推测,这些患者对EBV的免疫监视失调。我们回顾了55例转诊至美国国立癌症研究所进行前瞻性试验(1995年至2010年)的LYG患者的活检标本,并结合临床信息评估了这些活检标本的组织学、免疫组化、原位杂交和分子学结果。病变分级基于形态学特征和EBV阳性B细胞数量。中位年龄为46岁(男:女为2.2:1)。临床上,所有患者均有肺部受累(100%),其次最常见的部位是中枢神经系统(38%)。无患者有淋巴结或骨髓病变。所有患者血清学检查均曾接触过EBV,但EBV病毒载量中位数较低。我们回顾了122份活检标本;最常见的部位是肺部(73%),其次是皮肤/皮下组织(17%);其他部位包括肾脏、鼻腔、胃肠道、结膜、肝脏和肾上腺。组织学上,病变表现为血管中心性,富含T细胞,有大的非典型B细胞,且EBV呈阳性。分级主要在诊断时对肺部活检标本进行;分级分布如下:LYG 1级(30%)、2级(22%)和3级(48%)。各级均可见坏死,高级别病变坏死程度更重。进行了免疫球蛋白基因重排研究,与1级(8%)相比,LYG 2级(50%)和3级(69%)中克隆性重排的百分比更高。LYG是一种独特的疾病实体,通常可根据临床表现、组织学和EBV研究结果与其他与EBV相关的B细胞淋巴增殖性疾病相鉴别。这些病变的分级很重要,因为它决定了治疗选择。